Abstract:Chimeric antigen receptor (CAR) T-cell therapy has proven a breakthrough in cancer treatment in the last decade, giving unprecedented results against hematological malignancies. All approved CAR T-cell products, as well as many being assessed in clinical trials, are generated using viral vectors to deploy the exogenous genetic material into T-cells. Viral vectors have a long-standing clinical history in gene delivery, and thus underwent iterations of optimization to improve their efficiency and safety. Nonetheless, their capacity to integrate semi-randomly into the host genome makes them potentially oncogenic via insertional mutagenesis and dysregulation of key cellular genes. Secondary cancers following CAR T-cell administration appear to be a rare adverse event. However several cases documented in the last few years put the spotlight on this issue, which might have been underestimated so far, given the relatively recent deployment of CAR T-cell therapies. Furthermore, the initial successes obtained in hematological malignancies have not yet been replicated in solid tumors. It is now clear that further enhancements are needed to allow CAR T-cells to increase long-term persistence, overcome exhaustion and cope with the immunosuppressive tumor microenvironment. To this aim, a variety of genomic engineering strategies are under evaluation, most relying on CRISPR/Cas9 or other gene editing technologies. These approaches are liable to introduce unintended, irreversible genomic alterations in the product cells. In the first part of this review, we will discuss the viral and non-viral approaches used for the generation of CAR T-cells, whereas in the second part we will focus on gene editing and non-gene editing T-cell engineering, with particular regard to advantages, limitations, and safety. Finally, we will critically analyze the different gene deployment and genomic engineering combinations, delineating strategies with a superior safety profile for the production of next-generation CAR T-cell.

Engineering strategies to safely drive CAR T-cells into the future

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review

Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing

CAR T cells: Building on the CD19 paradigm

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Tuning CAR T-cell therapies for efficacy and reduced toxicity

ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights

Strategies to Enhance the Therapeutic Efficacy, Applicability, and Safety of Genetically Engineered Immune Cells

CRISPR/Cas-based CAR-T cells: production and application

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy

The Past, Present, and Future of Non-Viral CAR T Cells

CAR T-Cell Therapy: Progress and Prospects

Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility

Non-viral vectors for chimeric antigen receptor immunotherapy

Building Potent Chimeric Antigen Receptor T Cells with CRISPR Genome Editing

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy

Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells